Dr. Nickel discusses the safety of novel recurrent UTI vaccine

“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.

In this video, J. Curtis Nickel, MD, discusses the safety of the MV140 vaccine, used to treat patients with recurrent urinary tract infections. Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.

Related Content:

Female UrologyUTv
Questions raised by kidney cancer epidemiology update
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
Breakthrough Advances in Immunotherapy